Issue

Vol. 64 No. 3: Issue 3

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

TGFβ1-mediated expression and alternative splicing of Fibronectin Extra Domain A in human podocyte culture

https://doi.org/10.14715/cmb/2018.64.3.4
Tarunkumar Hemraj Madne
Southwest Thames Institute for Renal Research, Renal Unit, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, SM5 1AA, St Georges, University of London. London, United Kingdom
Mark Edward Carl Dockrell
Southwest Thames Institute for Renal Research, Renal Unit, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, SM5 1AA, St Georges, University of London. London, United Kingdom

Corresponding Author(s) : Tarunkumar Hemraj Madne

tarun2madne@yahoo.co.in

Cellular and Molecular Biology, Vol. 64 No. 3: Issue 3

Abstract

Alternative splicing is a fundamental phenomenon to build protein diversity in health and diseases. Extra Domain A+ Fibronectin (EDA+Fn) is an alternatively spliced form of fibronectin protein present in the extra cellular matrix (ECM) in renal fibrosis. Podocytes are spectacular cell type and play a key role in filtration and synthesise ECM proteins in renal physiology and pathology. TGFβ1 is a strong stimulator of ECM proteins in renal injury. In this study, we have investigated alternative splicing of EDA+ Fn in human podocytes in response to TGFβ1. We have performed western blotting and immunofluorescence to characterise the expression of the EDA+Fn protein, real-time PCR for RNA expression and RT-PCR to look for alternative splicing of EDA+Fn in conditionally immortalised human podocytes culture.We used TGFβ1 as a stimulator and SB431542 and SRPIN340 for inhibitory studies. In this work, for the first time we have demonstrated in human podocytes culture EDA+Fn is expressed in the basal condition and TGFβ1 2.5ng/ml induced the Fn mRNA and EDA+Fn protein expression demonstrated by real-time PCR, western blotting and immunofluorescence. TGFβ1 2.5ng/ml induced the alternative splicing of EDA+Fn shown by conventional RT-PCR. Studies with ALK5 inhibitor SB431542 and SRPIN340 show that TGFβ1 induced alternative splicing of EDA+Fn was by the ALK5 receptor and the SR proteins.  In human podocytes culture, alternative splicing of EDA+Fn occurs at basal conditions and TGFβ1 further induced the alternative splicing of EDA+Fn via ALK5 receptor activation and SR proteins. This is the first evidence of basal and TGFβ1 mediated alternative splicing of EDA+Fn in human podocytes culture.

Keywords

Extra Domain A Fibronectin Podocyte TGFβ1 Alternative splicing.
Madne, T. H., & Dockrell, M. E. C. (2018). TGFβ1-mediated expression and alternative splicing of Fibronectin Extra Domain A in human podocyte culture. Cellular and Molecular Biology, 64(3), 17–24. https://doi.org/10.14715/cmb/2018.64.3.4
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Kim E, Goren A, Ast G. Alternative splicing: current perspectives. Bioessays. 2008 Jan [cited 2013 Jan 2];30(1):38–47.
  2. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, et al. Function of alternative splicing. Gene . 2012 Aug 15 [cited 2012 Nov 4];514(1):1–30.
  3. Risso G, Pelisch F, Quaglino A, Pozzi B, Srebrow A. Regulating the regulators: serine/arginine-rich proteins under scrutiny. IUBMB Life. 2012 Oct [cited 2014 Dec 18];64(10):809–16.
  4. Lynch KW. Regulation of alternative splicing by signal transduction pathways. Adv Exp Med Biol. 2007 Jan [cited 2014 Dec 30];623:161–74.
  5. Blaustein M, Pelisch F, Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol. 2007 Jan [cited 2014 Dec 30];39(11):2031–48.
  6. Hallgren O, Malmström J, Malmström L, Andersson-Sjöland A, Wildt M, Tufvesson E, et al. Splicosomal and serine and arginine-rich splicing factors as targets for TGF-β. Fibrogenesis Tissue Repair. 2012 Jan [cited 2014 Dec 30];5(1):6.
  8. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem. 2005 Nov 25 [cited 2013 Jan 2];280(47):39616–26.
  10. Pankov R. Fibronectin at a glance. J Cell Sci. 2002 Oct 15 [cited 2012 Jul 13];115(20):3861–3.
  11. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair. 2011 Jan [cited 2012 Nov 20];4(1):21.
  13. Barnes VL, Musa J, Mitchell RJ, Barnes JL. Expression of Embryonic Fibronectin Isoform EIIIA Parallels -Smooth Muscle Actin in Maturing and Diseased Kidney. J Histochem Cytochem . 1999 Jun 1 [cited 2013 Jan 2];47(6):787–97.
  14. Mao Y, Schwarzbauer JE. Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol . 2005 Sep [cited 2012 Jul 15];24(6):389–99.
  15. Losino N, Waisman A, Solari C, Luzzani C, Espinosa DF, Sassone A, et al. EDA-containing fibronectin increases proliferation of embryonic stem cells. PLoS One. 2013 Jan [cited 2014 Dec 26];8(11):e80681.
  16. Pankov R. Fibronectin at a glance. J Cell Sci. 2002 Oct 15 [cited 2014 Oct 14];115(20):3861–3.
  17. Muro AF, Caputi M, Pariyarath R, Pagani F, Buratti E, Baralle FE. Regulation of fibronectin EDA exon alternative splicing: possible role of RNA secondary structure for enhancer display. Mol Cell Biol. 1999 Apr [cited 2014 Dec 30];19(4):2657–71.
  18. Muro AF, Iaconcig A, Baralle FE. Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5"² splicing site. FEBS Lett. 1998 Oct 22 [cited 2014 Dec 30];437(1–2):137–41.
  19. Baelde HJ, Eikmans M, van Vliet AI, Bergijk EC, de Heer E, Bruijn JA. Alternatively spliced isoforms of fibronectin in immune-mediated glomerulosclerosis: the role of TGFbeta and IL-4. J Pathol. 2004 Nov [cited 2014 Dec 30];204(3):248–57.
  20. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010 Dec 15 [cited 2012 Jul 14];123(Pt 24):4195–200.
  21. Muro AF, Moretti F a, Moore BB, Yan M, Atrasz RG, Wilke C a, et al. An essential role for fibronectin extra type III domain A in pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Mar 15 [cited 2012 Sep 7];177(6):638–45.
  22. Olsen AL, Sackey BK, Marcinkiewicz C, Boettiger D, Wells RG. Fibronectin extra domain-A promotes hepatic stellate cell motility but not differentiation into myofibroblasts. Gastroenterology. 2012 Apr [cited 2014 Dec 30];142(4):928–937.e3.
  23. Phanish MK, Heidebrecht F, Nabi ME, Shah N, Niculescu-Duvaz I, Dockrell MEC. The regulation of TGFβ1 induced fibronectin EDA exon alternative splicing in human renal proximal tubule epithelial cells. J Cell Physiol. 2014 Jun 24 [cited 2014 Oct 28];(November 2013):1–39.
  24. Li JH, Huang XR, Zhu H-J, Johnson R, Lan HY. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003 Jun;63(6):2010–9.
  25. Kanwar YS. TGF-β and renal fibrosis: a Pandora's box of surprises. Am J Pathol. 2012 Oct [cited 2013 Jan 8];181(4):1147–50.
  26. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int. 1996 Feb [cited 2014 Oct 28];49(2):461–9.
  27. Byron A, Randles MJ, Humphries JD, Mironov A, Hamidi H, Harris S, et al. Glomerular cell cross-talk influences composition and assembly of extracellular matrix. J Am Soc Nephrol. 2014 May [cited 2014 Dec 30];25(5):953–66.
  28. Patrakka J, Tryggvason K. Molecular make-up of the glomerular filtration barrier. Biochem Biophys Res Commun. 2010 May 21 [cited 2014 Dec 23];396(1):164–9.
  29. Gunwar S, Ballester F, Noelken ME, Sado Y, Ninomiya Y, Hudson BG. Glomerular Basement Membrane: identification of a novel disulfide-cross-linked network of 3, 4, and 5 chains of type iv collagen and its implications for the pathogenesis of alport syndrome. J Biol Chem. 1998 Apr 10 [cited 2014 Dec 30];273(15):8767–75.
  30. Miner JH. The glomerular basement membrane. Exp Cell Res. 2012 May 15 [cited 2014 Dec 30];318(9):973–8.
  32. Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, et al. Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. J Am Soc Nephrol. 1995 Aug [cited 2014 Dec 27];6(2):286–94.
  33. Viedt C, Bürger a, Hänsch GM. Fibronectin synthesis in tubular epithelial cells: up-regulation of the EDA splice variant by transforming growth factor beta. Kidney Int. 1995 Dec;48(6):1810–7.
  34. Kohan M, Muro AF, White ES, Berkman N. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J. 2010 Nov [cited 2014 Oct 10];24(11):4503–12.
  35. White ES, Sagana RL, Booth AJ, Yan M, Cornett AM, Bloomheart CA, et al. Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Exp Cell Res. 2010 Oct 1 [cited 2014 Oct 28];316(16):2644–53.
  36. Herman-Edelstein M, Thomas MC, Thallas-Bonke V, Saleem M, Cooper ME, Kantharidis P. Dedifferentiation of immortalized human podocytes in response to transforming growth factor-β: a model for diabetic podocytopathy. Diabetes. 2011 Jun [cited 2012 Sep 27];60(6):1779–88.
  37. Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008 Feb [cited 2014 Oct 28];172(2):299–308.
  38. Mullen AC, Orlando D a, Newman JJ, Lovén J, Kumar RM, Bilodeau S, et al. Master transcription factors determine cell-type-specific responses to TGF-β signaling. Cell. 2011 Oct 28 [cited 2014 Jul 10];147(3):565–76.
  40. Dong Z, Noda K, Kanda A, Fukuhara J, Ando R, Murata M, et al. Specific inhibition of serine/arginine-rich protein kinase attenuates choroidal neovascularization. Mol Vis. 2013 Jan [cited 2014 Dec 29];19(July 2012):536–43.
  41. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem. 2010 Feb 19 [cited 2014 Oct 23];285(8):5532–40.
Read More

Author Biography

Tarunkumar Hemraj Madne, Southwest Thames Institute for Renal Research, Renal Unit, St Helier Hospital, Wrythe Lane, Carshalton, Surrey, SM5 1AA, St Georges, University of London. London, United Kingdom
Mark Edward Carl Dockrell
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 864 Download : 372